Jump to main content
Jump to site search


Phosphotyrosine Prodrugs: Design, Synthesis and Anti-STAT3 Activity of ISS-610 Aryloxy Triester Phosphoramidate Prodrugs

Abstract

Unmasked phohate groups of phosphotyrosine-containing molecules carry two negative charges at physiological pH, which compromise their (passive) celular uptake. Also, these phosphate groups are often cleaved off by phosphatases. Together, these ultimately limit the pharmacological efficacy of the phosphotyrosine-containing compounds. To address these drawbacks, we herein present the application of the aryloxy triester phosphoramidate prodrug technology, a monophosphate prodrug technology, to the phosphotyrosine-containing compound ISS-610-Met, an analogue of the anticancer STAT3 dimerization inhibitor ISS-610. Our data shows that the generated ISS-610-Met prodrugs exhibited enhanced pharmacological activity and inhibition of STAT3 downstream signaling compared to the parent compound ISS-610-Met and the known STAT3 dimerization inhibitor ISS-610. These encouraging results provide a compelling proof of concept for the potential of the aryloxy triester phosphoramidate prodrug technology in the discovery of novel therapeutics that contain phosphotyrosine and its phospho mimics.

Back to tab navigation

Supplementary files

Publication details

The article was received on 10 May 2018, accepted on 06 Nov 2018 and first published on 07 Nov 2018


Article type: Research Article
DOI: 10.1039/C8MD00244D
Citation: Med. Chem. Commun., 2018, Accepted Manuscript
  •   Request permissions

    Phosphotyrosine Prodrugs: Design, Synthesis and Anti-STAT3 Activity of ISS-610 Aryloxy Triester Phosphoramidate Prodrugs

    A. Miccoli, B. Dhiani and Y. Mehellou, Med. Chem. Commun., 2018, Accepted Manuscript , DOI: 10.1039/C8MD00244D

Search articles by author

Spotlight

Advertisements